Ruxolitinib (Opzelura) for Atopic Dermatitis

Date: January 24, 2022 Issue #:  1642Summary:  The FDA has approved a 1.5% topical cream formulation of the Janus kinase (JAK) inhibitor ruxolitinib (Opzelura– Incyte) for short-term, non-continuous chronic treatment of mild to moderate atopic dermatitis (AD) in non-immunocompromised patients≥12 years old whose disease has not been adequately controlled with other topical prescription drugs. Ruxolitinib is the first JAK inhibitor to be approved for topical use and the first to be approved in the US for treatment of AD. An oral formulation of ruxolitinib(Jakafi) is approved for treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
Source: The Medical Letter - Category: Drugs & Pharmacology Authors: Tags: Atopic dermatitis corticosteroids crisaborole Elidel Eucrisa Jakafi Jakavi Opzelura Pimecrolimus Protopic ruxolitinib Tacrolimus tofacitinib Xeljanz Source Type: research